Beijing, January 20, 2019 -- Biopharmaceutical company Boya Jiyin and Cell Ecology Haihe Laboratory recently signed a strategic cooperation research and development agreement, the two sides will jointly promote the research and development and transformation of hematopoietic stem cells and the landing of gene therapy related technologies and products based on their respective technical and resource advantages, and create an original innovative research and clinical transformation platform for Hematopoietic stem cell therapy in China.
The Haihe Laboratory of Cell Ecology is a new type of R&D institution dedicated to basic research, technological innovation and achievement transformation of cell ecology, relying on the construction of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology of the Chinese Academy of Medical Sciences). The laboratory is of great strategic significance for gathering high-end innovation resources in the global cell industry, building a biomedical industry cluster that leads the high-quality development of the life and health industry, and supports the global appeal.
According to the cooperation agreement, the two sides will carry out a series of research cooperation in the field of hematopoietic stem cell regenerative therapy, including the development of innovative gene-modified hematopoietic stem cell therapy for specific Chinese blood genetic diseases, and the exploration of new hematopoietic stem cell biomarkers to optimize the quality control process of stem cell production.
"Cell technology and cell drugs are an important breakthrough in the future change of medical treatment models, giving full play to the advantages of the national platform and promoting the combination of production, education and research are important ways to achieve the transformation of cell technology and the landing of products." Professor Cheng Tao, executive deputy director of the Haihe Laboratory of Cell Ecology and president of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology of the Chinese Academy of Medical Sciences), said that hematopoietic stem cells have long-term self-renewal ability and the potential to differentiate into various mature blood cells, and around the research and therapy transformation of hematopoietic stem cells, it is expected to bring solutions to various diseases such as hematological tumors, autoimmune diseases, hereditary blood diseases and so on. It is believed that this cooperation can accelerate the promotion of source technological innovation and achievement transformation in the field of hematopoietic stem cells, and provide new means of guaranteeing people's health.
In 2021, Boya Ji launched the Phase I multi-center clinical trial of ET-01, The first gene-edited hematopoietic stem cell therapy research product for transfusion-dependent β thalassemia in China, and completed the first patient enrollment in the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences). At present, the clinical trial is being carried out in a number of clinical centers in Tianjin and the Guangdong-Hong Kong-Macao Greater Bay Area.
Dr. Wei Dong, CEO of Boya Jiyin, said that the cooperation with Haihe Laboratory of Cell Ecology will help further expand the layout and application in the field of hematopoietic stem cells, and through cooperation with top scientific research institutions, give full play to the company's transformation experience in the field of cell and gene therapy, and bring more independent innovation treatment solutions to patients in China and even the world as soon as possible. (End)
Source: China News Network
![Only to hold hands with the dream (1) to remember my father Feng Hai[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)